（来源：每财网） 来源：市场资讯 多数新势力车企业绩狂奔，然而蔚来仍然巨额亏损，已被同行甩在身后。 文/每日财报 楚风 蔚来再交出一份巨额亏损的成绩单。正当成立11周年之际，蔚来发布2025年第三季报，公司实现营收与 净利润双增长，但是净利润仍亏损34.81亿元。今年前三季度，蔚来累计亏损逾152亿元，与去年同期大 抵持平。 随着汽车销量增长，蔚来创始人李斌表示，有信心在今年四季度盈利。然而此言一出，就有机构出 来"打脸"。招商国际表示，预计蔚来第四季度仍可能实现净亏损16亿元，无法实现盈亏平衡。 《每日财报》发现，相比其他造车新势力，蔚来已被远远甩在后面。理想汽车早已在2023年盈利，零跑 汽车以及小米汽车也在今年迈入盈利行列，小鹏汽车业绩大幅减亏，而蔚来仍处于巨额亏损中。 但是不得不承认蔚来强大的融资能力。今年9月份，蔚来完成11.6亿美元股权发行，有效缓解现金流问 题。截止三季度末，公司现金储备达到367亿元，环比增长近百亿元，但长期来看仍然面临资金压力， 负债总额在持续攀升。 交出史上最好季报， 四季度能否盈利？ 11月25日，是蔚来成立11周年，同时披露了三季报。这堪称是蔚来史上最好的季报，实现营收 ...

Core Insights - The company, Mindray Medical, has encountered a significant slowdown in revenue growth, with 2024 revenue at 36.73 billion yuan, marking a drastic decline to 5.14% growth, the lowest since its A-share listing in 2018 [1] - The net profit attributable to shareholders was 11.67 billion yuan, showing a minimal increase of 0.74% [1] - The company's employee stock ownership plan faced a "failure to unlock" due to unmet performance targets, resulting in the management committee reclaiming shares [1] Business Performance - Mindray Medical's double-digit growth, a hallmark of its performance from 2018 to 2023, has come to a halt in 2024 [2] - The in-vitro diagnostics segment has become the largest revenue source, generating approximately 13.765 billion yuan with a year-on-year growth of 10.82% [2] - The medical imaging segment reported revenue of 7.498 billion yuan, growing by 6.6%, while the previously dominant life information and support segment saw a revenue decline of 11.11% to 13.557 billion yuan [2] Market Dynamics - The international market for Mindray Medical showed strong performance with a revenue increase of 21.28%, accounting for about 45% of total revenue [3] - The Asia-Pacific region, particularly Australia, Thailand, and India, experienced nearly 40% growth, while the European market rebounded over 30% [3] - Conversely, the domestic market faced challenges, with a revenue decline of 5.1% due to sluggish hospital equipment procurement and the impact of the DRG 2.0 policy [3] Future Outlook - Mindray Medical is seeking recovery, noting signs of sustained improvement in domestic medical equipment procurement since December of the previous year [4] - Despite a year-on-year decline of over 20% in the first quarter, there was a more than 50% quarter-on-quarter growth compared to the last quarter of the previous year [4] - The company anticipates a "front low and back high" performance trend in 2025, with a significant turning point in overall revenue growth expected to emerge in the third quarter [4]